Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI -6.39%26 Days Sales Outstanding is 46.69 as of Jun. 2026, which is 7% below its 10-year median of 50.39. GuruFocus rates TLSI with a GF Score™ of 26/100 and a GF Value™ of $3.77 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 812 Medical Devices & Instruments companies, TriSalus Life Sciences ranks better than 75.25% on this metric.
The historical rank and industry rank for TriSalus Life Sciences's Days Sales Outstanding or its related term are showing as below:
TLSI'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.89 Med: 50.39 Max: 58.96
Current: 46.65
During the past 5 years, TriSalus Life Sciences's highest Days Sales Outstanding was 58.96. The lowest was 42.89. And the median was 50.39.
TLSI's Days Sales Outstanding is ranked better than 75.25% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs TLSI: 46.65
TriSalus Life Sciences's Days Sales Outstanding
increased
from Jun. 2025 (44.86) to Jun. 2026 (46.69).
TriSalus Life Sciences (NAS:TLSI) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
TriSalus Life Sciences Days Sales Outstanding Related Terms
TriSalus Life Sciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Days Sales Outstanding Chart
TLSI vs TMCI, SENS, SGHT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Days Sales Outstanding falls into.
TriSalus Life Sciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a Days Sales Outstanding of 46.69 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on TriSalus Life Sciences and its competitors. This is near median its historical median of 50.39. Over the past decade, TriSalus Life Sciences' Days Sales Outstanding has ranged from 42.89 to 58.96. According to the industry distribution chart, TriSalus Life Sciences ranks #201 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 24.8%.
Is TriSalus Life Sciences' Days Sales Outstanding too high?
TriSalus Life Sciences' current Days Sales Outstanding of 46.69 is near median its 10-year median of 50.39. Over the past 10 years, this metric has ranged from a low of 42.89 to a high of 58.96. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. TriSalus Life Sciences' value of 46.69 is 28.4% below this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #201 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Days Sales Outstanding compare to TMCI and SENS?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #201 out of 812 companies for Days Sales Outstanding. This places TriSalus Life Sciences in the top 25% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 65.17. TriSalus Life Sciences' value of 46.69 is 28.4% below this benchmark. Historically, TriSalus Life Sciences' own Days Sales Outstanding has ranged from 42.89 to 58.96 over the past decade. While the company's 10-year median is 50.39 vs. the industry median of 65.17, TriSalus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Days Sales Outstanding of 46.69 is 28.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Days Sales Outstanding is 46.69, which is near median its own 10-year median of 50.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.77, compared to a current price of $5.25 — trading 39.3% above its estimated fair value. The current Days Sales Outstanding is 46.69, which is near median its 10-year median of 50.39 and 28.4% below the Medical Devices & Instruments industry median of 65.17. TriSalus Life Sciences' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Days Sales Outstanding is 46.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $5.25 is trading 39.3% above its estimated GF Value™ of $3.77.
GuruFocus considers TriSalus Life Sciences to be Significantly Overvalued.
Key valuation signals for TLSI:
Days Sales Outstanding: 46.69 (near median its 10-year median of 50.39)
GF Value™: $3.77 vs. price of $5.25 (39.3% above fair value)
Industry Position: 28.4% below the Medical Devices & Instruments median (#201 of 812)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
26GF Score
Get the complete analysis for TLSI
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
